Lunai Bioworks Statistics
Total Valuation
Lunai Bioworks has a market cap or net worth of $10.93 million. The enterprise value is $9.18 million.
| Market Cap | 10.93M |
| Enterprise Value | 9.18M |
Important Dates
The next estimated earnings date is Monday, September 28, 2026, after market close.
| Earnings Date | Sep 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lunai Bioworks has 4.53 million shares outstanding. The number of shares has increased by 39.92% in one year.
| Current Share Class | 4.53M |
| Shares Outstanding | 4.53M |
| Shares Change (YoY) | +39.92% |
| Shares Change (QoQ) | +6.44% |
| Owned by Insiders (%) | 29.07% |
| Owned by Institutions (%) | 3.46% |
| Float | 2.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 521.76 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 438.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.16 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -247.28 |
Financial Efficiency
Return on equity (ROE) is -325.46% and return on invested capital (ROIC) is -14.02%.
| Return on Equity (ROE) | -325.46% |
| Return on Assets (ROA) | -9.65% |
| Return on Invested Capital (ROIC) | -14.02% |
| Return on Capital Employed (ROCE) | 1,417.17% |
| Weighted Average Cost of Capital (WACC) | 8.77% |
| Revenue Per Employee | $722 |
| Profits Per Employee | -$4.42M |
| Employee Count | 29 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.46% in the last 52 weeks. The beta is 0.32, so Lunai Bioworks's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -87.46% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 4.89 |
| Relative Strength Index (RSI) | 45.87 |
| Average Volume (20 Days) | 475,095 |
Short Selling Information
The latest short interest is 121,746, so 2.69% of the outstanding shares have been sold short.
| Short Interest | 121,746 |
| Short Previous Month | 150,195 |
| Short % of Shares Out | 2.69% |
| Short % of Float | 4.17% |
| Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Lunai Bioworks had revenue of $20,942 and -$128.28 million in losses. Loss per share was -$46.23.
| Revenue | 20,942 |
| Gross Profit | 20,942 |
| Operating Income | -9.85M |
| Pretax Income | -128.28M |
| Net Income | -128.28M |
| EBITDA | -133.42M |
| EBIT | -133.53M |
| Loss Per Share | -$46.23 |
Balance Sheet
The company has $3.16 million in cash and $1.41 million in debt, with a net cash position of $1.74 million or $0.38 per share.
| Cash & Cash Equivalents | 3.16M |
| Total Debt | 1.41M |
| Net Cash | 1.74M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | -9.55M |
| Book Value Per Share | -2.14 |
| Working Capital | -15.55M |
Cash Flow
In the last 12 months, operating cash flow was -$5.26 million and capital expenditures -$1,238, giving a free cash flow of -$5.26 million.
| Operating Cash Flow | -5.26M |
| Capital Expenditures | -1,238 |
| Depreciation & Amortization | 76,992 |
| Net Borrowing | 3.93M |
| Free Cash Flow | -5.26M |
| FCF Per Share | -$1.16 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -47,019.40% |
| Pretax Margin | -612,568.11% |
| Profit Margin | n/a |
| EBITDA Margin | -637,105.86% |
| EBIT Margin | -637,607.08% |
| FCF Margin | n/a |
Dividends & Yields
Lunai Bioworks does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.92% |
| Shareholder Yield | -39.92% |
| Earnings Yield | -1,174.04% |
| FCF Yield | -48.13% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 22, 2026. It was a reverse split with a ratio of 1:8.
| Last Split Date | May 22, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:8 |
Scores
Lunai Bioworks has an Altman Z-Score of -76.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -76.7 |
| Piotroski F-Score | 2 |